U.S. markets open in 4 hours 8 minutes

111, Inc. (YI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.09+0.10 (+0.91%)
At close: 4:00PM EDT

12.50 +1.41 (12.71%)
Pre-Market: 5:21AM EDT

Sign in to post a message.
  • M
    Citi analyst Zoe Bian just kept a Buy rating with a $16 price target.
  • 5
    the Chinese subsidiary of Yi is going public on the stock platform there and have gotten more than 10 institutions subscribing to it pre-ipo.
    the subsidiary's valuation is at 1.5B now and i am just confused why Yi at Nasdaq is not even at 1B valuation
  • j
  • T
    Hedge funds seem to be snapping this up after hours and then it goes back down during normal market hours... earnings around the corner will be interesting
  • S
    Glory Star New Media Group Holdings Limited
    earnings on 29th March.
    lookout for this one, $jd $PDD $VIPS $QD $YI.
    GSMG Cheers Emall Live shopping will be the next big platform in China!
  • T
    Excellent earnings and still almost -6% down this stock continues to baffle me. I appreciate it’s a Red day in general but was up 10% in the premarket!
  • T
    Am I missing something?

    111 (NASDAQ:YI) is a leader in the online pharmacy industry in China. It partners with local drugstores to deliver a wide array of products to the consumer's doorstep, among them prescription pharmaceuticals, Chinese medicines, nutritional supplements, medical devices, contact lenses, beauty items, and reproductive products.
    Management is nearing its goal of extending its reach to more than 300,000 pharmacies in China -- 57% of the country's total, serving more than 1 billion people. The prescription medicine market in China amounts to 300 billion yuan (approximately $46 billion) annually.
    Since its IPO in 2018, 111 has delivered eight consecutive quarters of growth. Back in Q3 2020, its revenue increased by a stunning 113% year over year to 2.363 billion yuan (about $366 million). At the same time, its non-GAAP net loss narrowed to just 4% of its revenue, compared to 10% in Q3 2019. 111 also expanded its order count by 297% to 1.14 million and doubled its number of partnerships with pharmaceutical companies to 301.
    The sky is the limit for 111. The company intends to offer new branded medications on its platform. This is significant as many Chinese consumers could previously only afford cheap generic variants. It also has plans to offer products that would target chronic illnesses such as diabetes.
    For all its growth and potential, you may be surprised to learn that the company is trading at just 2 times sales.

    How is this sooo cheap considering the huge growth and such a low!? I know people are cautious about Chinese companies but is that the only reason?
  • ד
    Amazing report, wat a winner
  • E
    TDOC just reported growth of +100%, annualized revenue of ~$1.5B...after hours dropped to a market cap of $36B
    YI annualized revenues are ~$1B and market cap is less than $2B

    Looking forward to next earnings - YI serves a market 4x the size of TDOC...share price could be $200/sh and they’d still only be half the size of TDOC on the same revenue stream
  • N
    Bought 1K yesterday, loading up on another 5k today! Amazing stock, very undervalued imho
  • F
    Hi, can someone explain my whats is wrong with this company / stock ? its suppose to be an hit stock but it have -63% past few weeks !! \
    its seem that tis is another Chinese style business model, or Im missing something
  • i
    JFYI. I've always seen YI and HUIZ as a pair, both portals, one medical, one online insurance product and service platform, both with a pretty unique position. Finally YI made the jump to triple, it can easily go another x2 in the short run. I believe the same will happen to HUIZ in the very short term.
  • C
    China Investor
    YI is a great company in the medical industry. Will the stock go higher?
    加入微信讨论群:To join the Chinese Investor Group, please add WeChat ID: ChinaInvestorGroup
  • E
    NASDAQ article on YI today... top 4 health companies to buy now
  • P
    Revenue growth was strong but slowing. Meanwhile margins have barely improved. Not a good combination.
  • J
    honest question... if your sales increase but your profits stay the same are you really a better company? YOY sales increase but EPS does not get any better and if you look just at gross profit it... the more they sale they are not getting anymore on there margins... so that said can you really value a company at 2x or 3x their sales when they cant turn a profit? just my thoughts... full disclosure i am short at 20 for this reason... i think this is going back down to the 12-15/share area... thoughts?
  • E
    Even after today:
    This is a $1.5B company doing +$1B in sales...
    Growing at 100% recently...
    Expanding meaningfully into Telehealth...
    In the fastest growing economy in the world...
    Focused on the most underserved parts of that economy (second tier cities...each one about the size of an LA or NYC, btw)...

    Looking forward to next ER
  • E
    The float on YI is only about 24M shares - a quarter of that sold just today, probably about half this week

    This is a pretty solid base at these price levels ...with good reason, YI is still very reasonably valued when comparing the revenue, market cap, and addressable market to other telehealth companies
  • 5
    what would be a price level where Yi should be consolidating on before the next run?
  • L
    Long wins!
    this is a 10-bagger easily